IMMX PE Ratio & Valuation, Is IMMX Overvalued

Historical Valuation

Immix Biopharma Inc (IMMX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.85. The fair price of Immix Biopharma Inc (IMMX) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：9.29

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Immix Biopharma Inc (IMMX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Immix Biopharma Inc (IMMX) has a current Price-to-Book (P/B) ratio of 21.70. Compared to its 3-year average P/B ratio of 5.45, the current P/B ratio is approximately 298.11% higher. Relative to its 5-year average P/B ratio of 4.31, the current P/B ratio is about 403.36% higher. Immix Biopharma Inc (IMMX) has a Forward Free Cash Flow (FCF) yield of approximately -5.40%. Compared to its 3-year average FCF yield of -23.56%, the current FCF yield is approximately -77.07% lower. Relative to its 5-year average FCF yield of -20.73%, the current FCF yield is about -73.95% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for IMMX competitors is 3.83, providing a benchmark for relative valuation. Immix Biopharma Inc Corp (IMMX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of IMMX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of IMMX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is IMMX currently overvalued or undervalued?

What is Immix Biopharma Inc (IMMX) fair value?

IMMX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Immix Biopharma Inc (IMMX) is between to according to relative valuation method.

How does IMMX's valuation metrics compare to the industry average?

The average P/S ratio for IMMX's competitors is 3.83, providing a benchmark for relative valuation. Immix Biopharma Inc Corp (IMMX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Immix Biopharma Inc (IMMX) as of Mar 09 2026?

As of Mar 09 2026, Immix Biopharma Inc (IMMX) has a P/B ratio of 21.70. This indicates that the market values IMMX at 21.70 times its book value.

What is the current FCF Yield for Immix Biopharma Inc (IMMX) as of Mar 09 2026?

As of Mar 09 2026, Immix Biopharma Inc (IMMX) has a FCF Yield of -5.40%. This means that for every dollar of Immix Biopharma Inc's market capitalization, the company generates -5.40 cents in free cash flow.

What is the current Forward P/E ratio for Immix Biopharma Inc (IMMX) as of Mar 09 2026?

As of Mar 09 2026, Immix Biopharma Inc (IMMX) has a Forward P/E ratio of -8.76. This means the market is willing to pay $-8.76 for every dollar of Immix Biopharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Immix Biopharma Inc (IMMX) as of Mar 09 2026?

As of Mar 09 2026, Immix Biopharma Inc (IMMX) has a Forward P/S ratio of 0.00. This means the market is valuing IMMX at $0.00 for every dollar of expected revenue over the next 12 months.

IMMX Valuation